Kplan教授回顾性研究-未发表.pdfVIP

e692 THE JOURNAL OF UROLOGY Vol. 183, No. 4, Supplement, Tuesday, June 1, 2010 provement relative to placebo in urinary symptoms and BPH progres- Table 1. Efficacy and tolerability measures after 4 years of treatment sion in LUTS patients with baseline PV 30 mL compared to those with with combination therapy or either monotherapy. baseline PV 30 mL. In addition, this data set represents the longest Previously treated Previously untreated DT D T DT D T follow up of any 5-ARI compared to placebo with respect to both n836 n836 n839 n746 n757 n747 efficacy as well as BPH progression. AUR or BPH-related Year 4 Results (ITT analysis population) surgery Baseline PV30 mL Baseline PV30 mL Crude incidence rate 4.7% 6.0% 12.6% 3.6% 4.5% 10.8% PBO FIN PBO FIN p value vs. — 0.23 0.001 — 0.39 0.001 Mean Change in AUA SS -5.2 -5.3 -4.6 -5.8 combination Mean Change in PV (mL) 7.3 0.3 8.8 -5.8 BPH clinical Mean Change in PVR (mL) -6.6 -7.5 7.3 -7.6 progression‡ Crude incidence rate 13.0% 18.5% 23.1% 11.9% 16.9% 19.9% Mean